At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITCI Intra-Cellular Therapies
Post-Market Trading 11-05 18:24:31 EST
89.24
+3.07
+3.56%
盘后89.44
+0.20+0.22%
17:22 EST
High89.44
Low85.08
Vol507.36K
Open85.79
D1 Closing86.17
Amplitude5.06%
Mkt Cap9.46B
Tradable Cap9.26B
Total Shares106.02M
T/O44.73M
T/O Rate0.49%
Tradable Shares103.74M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Intra-Cellular's schizophrenia drug meets main goal in late-stage trial
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating Caplyta for the Prevention of Relapse in Patients With Schizophrenia
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.